Onco-Innovations Limited Registered Shs WKN: A3EKSZ ISIN: CA68237C1059 Kürzel: ONNVF Forum: Aktien Thema: Hauptdiskussion

Auf jeden Fall kann man bei ING den Titel über die meisten deutschen Handelsplätze handeln.

Jop, ich. Der Titel hebt sich aus diversen Gründen von dem ab, was man sonst so mit Kanada assoziiert. Ich sehe hier Potenzial.

Hab mir auch eine kleine Menge gekauft, hört sich halbwegs seriös an

Ich sag mal so, zumindest klingt das deutlich besser als die milionste Mine aus der vllt. Oder vllt. auch nicht irgendwie mal was gefördert wird für 0,0005 €/Aktie: https://www.sciencedirect.com/science/article/pii/S016836592100208X Phosphatase and TENsin homolog deleted on chromosome 10 (PTEN) is a major tumor-suppressor protein that is lost in up to 75% of aggressive colorectal cancers (CRC). The co-depletion of PTEN and a DNA repair protein, polynucleotide kinase 3′-phosphatase (PNKP), has been shown to lead to synthetic lethality in several cancer types including CRC. This finding inspired the development of novel PNKP inhibitors as potential new drugs against PTEN-deficient CRC. Here, we report on the in vitro and in vivo evaluation of a nano-encapsulated potent, but poorly water-soluble lead PNKP inhibitor, A83B4C63, as a new targeted therapeutic for PTEN-deficient CRC. Our data confirmed the binding of A83B4C63, as free or nanoparticle (NP) formulation, to intracellular PNKP using the cellular thermal shift assay (CETSA), in vitro and in vivo. Dose escalating toxicity studies in healthy CD-1 mice, based on measurement of animal weight changes and biochemical blood analysis, revealed the safety of both free and nano-encapsulated A83B4C63, at assessed doses of ≤50 mg/kg. Nano-carriers of A83B4C63 effectively inhibited the growth of HCT116/PTEN−/− xenografts in NIH-III nude mice following intravenous (IV) administration, but not that of wild-type HCT116/PTEN+/+ xenografts. This was in contrast to IV administration of A83B4C63 solubilized with the aid of Cremophor EL: Ethanol (CE), which led to similar tumor growth to that of formulation excipients (NP or CE without drug) or 5% dextrose. This observation was attributed to the higher levels of A83B4C63 delivered to tumor tissue by its NP formulation. Our data provide evidence for the success of NPs of A83B4C63, as novel synthetically lethal nano-therapeutics in the treatment of PTEN-deficient CRC. This research also highlights the potential of successful application of nanomedicine in the drug development process.

So habe auch mal ein paar gekauft bin gespannt ob hieraus was wird hoffe auf Kurse um 3€ wäre toll 🥰

Jemand investiert?

Moin!